Chinese pharma company CF PharmTech has secured a $90 million Series E investment led by New Alliance Capital for accelerating the global development of respiratory drugs.

The investment round saw participation from new investors such as CR-CP Life Science Fund, Finnova Capital, Xiangcheng Financial, GT Capital, Co-stone Asset Management, and Everest Venture Capital. Existing investors like Oriza Holdings, Longmen Venture Capital, CMB International, and GTJA Investment also took part in the funding round.

CF PharmTech said that the completion of the funding round represents the strong support from Chinese investors to drive high-caliber pharmaceutical companies that have a strong competitive edge across the world. The investment is expected to enable the Chinese pharma company to roll out products in its pipeline to market.

Lei Cai – New Alliance Capital Executive Director said: “New Alliance Capital prioritizes investment opportunities in the healthcare industries. Respiratory treatments and inhaled medications, in particular, are promising because of the high technological barriers to entry and immense potential for growth. CF PharmTech has worked meticulously to build strong technological platforms that support the development of a comprehensive range of products. The integrity and professionalism of the core team at CF PharmTech impressed us deeply.”

CF PharmTech, which is dedicated to respiratory health, had built R&D and manufacturing facilities for inhalation products. Currently, the Chinese pharma company is engaged in expanding its pipeline of more than 20 products targeting China and global markets.

Da Liu – CR-CP Life Science Fund Managing Director said: “CF PharmTech is one of China’s most innovative and pioneering pharmaceutical companies to focus on respiratory disease treatments. As a pharma company, CF PharmTech fully embodies a commitment to quality and global standards. As one of the few leading private pharmaceutical companies of respiratory drug delivery, CF PharmTech has immense potential for growth.”

  CF PharmTech, China, Co-stone Asset Management, CR-CP Life Science Fund, Da Liu, Finnova Capital, GT Capital, New Alliance Capital, Xiangcheng Financial